APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH

APEPTICO Forschung und Entwicklung GmbH
Mariahilferstraße 136, Top 1.15
A-1150 Vienna, Austria
T: +43 664 1432919
E: b.fischer@apeptico.com
W: www.apeptico.com

APEPTICO is a privately-held biotechnology company, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures, APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.

APEPTICO develops the AP301 peptide family. AP301 peptides are water soluble molecules and can be administered into the lung by oral inhalation. Formulated AP301 is easily nebulised. AP301 and derived peptides are designed for activation of the pulmonary epithelial sodium channel (ENaC). Activation of ENaC by AP301 results in an accelerated lung oedema clearance in the airspace. AP301 peptides are effective in therapeutic treatment of various forms of pulmonary oedema. In addition to the use of AP301 for the treatment of patients suffering from life-threatening oedematous respiratory failure, the compound is assessed for the treatment of primary graft dysfunction following lung transplantation.

APEPTICO 是一家私人拥有的生物技术公司，以肽为基础开发针对慢性和威胁生命的疾病的产品。肽分子对应经过验证的药效学活性结构，以及知名的蛋白质结构域和药用生物分子。通过专注于合成的蛋白质结构，APEPTICO 能够避免基因和细胞技术带来的相关风险。 APEPTICO 利用其技术平台 PEPBASE（TM）和 PEPSCREEN（TM），显著降低了成本并缩短了产品的上市时间。

APEPTICO 开发了 AP301 肽家族。 AP301 肽是水溶性的分子，可以通过口服吸入到肺部。

制成的 AP301 容易雾化。 AP301 和衍生肽是为了激活肺上皮细胞钠离子通道（ENaC）而设计的。用 AP301 激活 ENaC 会加速清除肺部空气中的水肿。 AP301 肽可有效治疗各种形式的肺水肿。不仅可以使用 AP301 治疗患有危及生命的水肿呼吸衰竭的病人，该化合物现正在被鉴定是否可用于治疗肺移植后产生的原发性移植功能障碍。

BIOMAY AG

Biomay AG
Lazarettgasse 19/1
A-1090 Vienna
Austria
T: +43-1-7966-296-100
E : r.henning@biomay.com
W: www.biomay.com

R&D: Biomay discovers and develops innovative products for allergy immunotherapy based on a patent protected peptide carrier fusion protein platform. Our lead product BM32 is in phase II clinical trials. Our pipeline contains vaccines for all major airborne allergies. These products combine superior efficacy with improved safety and convenience.

Services: We offer contract manufacturing in mg to g scale for all clinical phases and market supply under GMP conditions. Our service offering is comprised of both proteins and plasmid DNA.

Indication: Respiratory diseases, allergy immunotherapy

Production: We manufacture recombinant allergens and other recombinant proteins in an E. coli based system.

Sales/Distribution: We distribute recombinant allergens for research and diagnostic use.

研发：在有专利保护的肽载体融合蛋白平台的基础上，Biomay 发现并开发了用于过敏免疫治疗的创新产品。我们的主导产品 BM32 目前处在 II 期临床试验阶段。除此之外我们研发针对所有的空气中主要过敏原的多种疫苗。这些产品均功效卓越，且具有更高的安全性和便利性。

服务：我们提供符合 GMP 条件的毫克到克范围不等的、用于所有临床阶段及供应市场的合同制造。我们能提供蛋白质和质粒 DNA。

适用于：呼吸系统疾病，过敏症免疫治疗

生产：在一个以大肠杆菌为基础的系统里，我们生产重组过敏原和其他重组蛋白。

销售/分销：本公司经销重组过敏原用于研究和诊断。

VIENNA UNIVERSITY OF TECHNOLOGY

Vienna University of Technology
Research and Transfer Support
Favoritenstrasse 16
A-1040 Vienna
Austria
E: helene.gruber@tuwien.ac.at
hildegard.sieberth@tuwien.ac.at
W: www.rt.tuwien.ac.at

The Vienna University of Technology has 3000 scientists at 52 advanced institutes working on Life Sciences, Computational Science and Engineering, Quantum Physics and Quantum Technologies, Materials and Matter, Information and Communication Technology and Energy and Environment. The university has expertise in high-tech problem solving and examination, performs applied research projects with innovative industrial clients and obtains a high amount of competitively awarded public and third party funding. It wants to find Chinese partners for collaboration and licensing:

- Photopolymerizable biopolymers for rapid prototyping of cellular bone replacement materials
- Biocompatible and biodegradable thermoplastic urethane Elastomers for electrospinning of vascular grafts
- Cardiogenesis inducing synthetic small molecules
- Enhancement of protein production by Trichoderma reesei (VEL 1)
- Biosynthesis of N-Acetylneuraminic acid (NeuNAc, NANA) from the renewable resource chitin using Trichoderma reesei as whole-cell biocatalyst
- Source-specific detection of Faecal Pollution
- Ultrasonically supported ATR Spectroscopy of suspensions in bioreactors
- Flowchiller - a peltier-assisted cooling device for batch and continuous flow chemistry

维也纳技术大学有 3000 名科学家在 52 个先进的机构从事生命科学、计算科学与工程，量子物理与量子技术，材料与物质，信息和通信技术以及能源与环境的研究。该大学拥有解决高科技难题和检测的专业知识，并与来自产业界的创新型客户一起进行应用项目的研究，经过激烈竞争获得了大量公共和第三方资金的支持。维也纳技术大学想在中国寻找合作伙伴并转让技术：

•细胞骨替代材料的快速成型的光聚合生物聚合物
•用于血管移植的电纺丝的生物相容性和生物可降解的热塑性聚氨酯弹性体
•心脏发育诱导合成小分子
•用里氏木霉（VEL1）增加蛋白质的产量
•使用里氏木霉作为全细胞生物催化剂的可再生资源甲壳素，生物合成 N-乙酰神经氨酸（NeuNAc，NANA）
•粪便污染的特定源检测
•在生物反应器里，对悬浮液进行超声波支持的 ATR 光谱分析
•Flowchiller：一款用于批次和连续流动化学的珀尔帖辅助冷却装置

VIRUSURE GMBH

ViruSure GmbH
Tech Gate Science Park
Donau-City-Straße 1
A-1220, Vienna, Austria.
T: +43 1 2699120
E : Andy_Bailey@virusure.com
W: www.virusure.com

ViruSure is a privately owned Austrian company specialising in the virus and prion safety testing of biopharmaceutical products. The company boasts a wealth of experience in various aspects of biosafety testing, and offers high quality and cost effective contract testing specifically tailored to meet the need of each product. Both our *in vitro* and *in vivo* facilities are certified to GLP/GMP standards to ensure a high standard for all our testing. Our customer service is second to none and we work together closely with all our customers to develop the best testing strategy for their product. Our reports have been submitted and accepted by regulatory authorities worldwide, including EMEA, PEI, AFSAPPS, FDA, KFDA, JMLHW and the TGA.

Our services include:

- Virus (using either infectivity or qPCR test systems)
- Prion clearance studies (via Western blot or bioassay titration)
- *In vitro* and *in vivo* adventitious agent testing
- Retrovirus testing (cell culture and molecular biology)
- PCR testing for virus contaminants
- Tumorigenicity and oncogenicity testing
- Cell banking
- Cell bank characterisation
- Master virus seed characterisation
- Bio-distribution studies
- Virus inhibition/interference tests (testing of antiviral substances)
- Virus safety assessments (consultancy services)

ViruSure 是一家私人拥有的奥地利公司，专门从事生物医药产品的病毒和朊病毒安全测试。公司拥有丰富的生物安全测试的各方面经验，并提供专为满足每种产品的需求而专门设置的高品质且符合成本效益的合同测试。我们体外和体内的设施均经过认证，符合 GLP / GMP 标准，确保高标准完成我们所有的测试。我公司的客户服务首屈一指。我们与客户一起紧密合作，开发符合他们产品的最佳测试策略。我们的报告已经提交并被全球多家监管机构所接受，包括 EMEA、PEI、AFSAPPS、 FDA、 KFDA、 JMLHW 以及 TGA。

我们的服务包括：

- 病毒（使用传染性或定量 PCR 检测系统）
- 朊病毒清除研究（通过 Western blot 检测或生物测定滴定法）
- 在体外和体内的外源因子检测
- 逆转录病毒检测（细胞培养和分子生物学）
- PCR 检测病毒污染物
- 致瘤性及致癌性试验
- 细胞银行
- 细胞银行表征
- 主病毒种子特性
- 生物分布研究
- 病毒抑制/干扰试验（抗病毒物质测试）
- 病毒安全性评估（咨询服务）

INOXIA LIFESCIENCES GMBH

INOXIA Lifesciences GmbH
Erlgasse 48
A-1120 Vienna, Austria
T: +43 1 8105366
E: akubin@inoxia.at
W: www.inoxia.at

Novel EPO inhibitors for treating auto enzyme induced diseases - Early discovery project for licensing of new treatment solutions for eg. ulcerative colitis (UC).

In inflammation, the eosinophil granulocytes release the enzyme eosinophil peroxidase (EPO), which fight off invading microbes in the colon. An overproduction of EPO can result in ulcerative colitis. Our treatment solution is the development of inhibitors against the enzyme EPO. Efficacy of EPO inhibitors were tested in a mouse model. We used histological scoring according to Dieleman et al. For comparison, we used Mesalazine which is a standard treatment for colitis, and Resorcinol as an unspecific quencher of oxygen radicals. We found a significant relief of the inflammatory processes and high efficacy of EPO inhibitors compared to Mesalazine and Resorcinol.

Our goal is to bring the product to an advanced clinical stage of development within 5 years of signing an agreement with an industrial partner. We are open for a joint development together with a partner who has sufficient financial capability and who can contribute expertise in preclinical and clinical development. Our estimated total budget for five years is Euro 8 Mio. The main exit channel for investors is a trade deal and in this regard we are in continuous contact with pharmaceutical companies interested in our portfolio.

新型酶嗜酸性粒细胞过氧化物酶抑制剂用于治疗酶引起的疾病——新治疗方式的早期发现项目许可，例如溃疡性结肠炎。

在炎症中，嗜酸粒细胞释放酶嗜酸性粒细胞过氧化物酶（EPO），抵抗入侵结肠的微生物。酶嗜酸性粒细胞过氧化物酶的过度产生会导致溃疡性结肠炎。我们的治疗方案是开发针对酶嗜酸性粒细胞过氧化物酶（EPO）的抑制剂。我们用小白鼠测试了酶嗜酸性粒细胞过氧化物酶抑制剂的药效。过程中我们使用了 Dieleman 等人的组织学评分方法。为进行比较，我们使用治疗结肠炎的常规药物美沙拉嗪，以及作为氧自由基的非特异性猝灭剂的间苯二酚。结果发现使用酶嗜酸性粒细胞过氧化物酶抑制剂后，炎症过程得到显著缓解，并且与美沙拉嗪和间苯二酚相比，酶嗜酸性粒细胞过氧化物酶抑制剂（EPO）的疗效要高得多。

我们的目标是和企业合作伙伴签订协议，在 5 年之内完成产品开发的高级临床分期。热忱欢迎拥有财力雄厚并能够在临床前及临床开发阶段贡献专长的合作伙伴，与我们一起共同开发产品。预计五年总预算为 800 万欧元。投资者的主要退出渠道是一个贸易协定，在这方面我们将与有兴趣和我们合作的制药公司保持持久的联系。

SCARLETRED BIOMEDICALS E.U.

SCARLETRED Biomedicals e.U.
Würffelgasse 4/66
1150 Vienna, Austria
T: +43 664 8850 6246
E: harald.schnidar@scarletred.at
W: www.scarletred.at

SCARLETRED Biomedicals develops innovative products for augmented diagnostics, personalized medicine and therapy.

Medical teams examine dermatologic conditions mainly by the eye. This leads to high variability and often hardly traceable results, especially when exploring small study populations during clinical Phase I or in multicentric clinical trials. Thus development risks increase especially for smaller biotech companies with rather limited resources.

The patented SCARLETRED® skin imaging and analysis technology is a game changer. It was developed during clinical Phase I drug testing in radiotherapy treated cancer patients suffering from radiation dermatitis. Comprising of a web based analysis platform and a remotely manageable APP, patient images are easily generated, normalized and automatically transferred in a GCP conform process to the licensee. This enables real-time patient monitoring and time resolved analysis of skin or mucosal conditions. SCARLETRED® is objective, highly standardized, cost efficient and scalable up to a global trial level. It reduces post-study analysis time, development risks and opportunity costs. Leading biomedical e-data quality and safety standards are assured by technical cooperation with RISE, the developer of the German e-health card architecture.

SCARLETRED Biomedicals 公司开发了一些为增强诊断、个性化的医药和治疗创新产品。

医疗队伍主要是用肉眼检查皮肤病。这导致具有高变异性且往往难以溯源的结果。这在临床 I 期或在多中心试验中探索研究少量样本时尤为如此。这样一来，开发中的风险无疑会增加，特别是对那些拥有非常有限资源的小型生物技术公司而言。

而这项已经申请专利的 SCARLETRED®皮肤成像和分析技术则改变了游戏规则。在为患放射性皮炎的癌症患者进行放射治疗的临床 I 期药物试验阶段开发了这项技术。该技术包括一个基于 Web 的分析平台和一个可远程管理的 APP，病人影像容易生成且被规范化地自动转入 GCP 流程，为持证人所获取。这实现了对病人的实时检测以及对皮肤或皮肤粘膜情况的时间分辨分析。SCARLETRED®技术是客观且高度标准化的，其成本效益高，并可扩展到一个全球性试验水平。它减少了后期的研究分析时间，降低了开发风险和机会成本。通过与德国电子医保卡的架构者——RISE 的技术合作，保证了这项领先的生物医学的电子数据质量及其安全标准。

BILFINGER INDUSTRIETECHNIK SALZBURG GMBH

Bilfinger Industrietechnik Salzburg GmbH
Bergerbräuhofstraße 31
5020 Salzburg, Austria
T: +43 662 8695-0
F: +43 662 8695-994
E: Office.salzburg@bilfinger.com
W: www.it-salzburg.bilfinger.com

中国区联系方式
上海市淮海东路 99 号恒基大厦 13 楼
邮编 200021
T: +86 (21) 2309 9966 分机 2529
F: +86 (21) 2309 9968
M : +86 13761045003
E: Gang.Chen@bilfinger.com

We engineer, fabricate and assemble piping, systems and equipment in the biotechnology, pharmaceuticals and fine chemicals industries. Besides our European locations, we serve our customers through operations in China and South Korea. We have been applying our wide knowledge and structured methods for over 50 years and are well known far beyond Salzburg.

We offer innovative stainless steel bioreactor lines for both microbial fermentation and cell culture. Our design is modular with state-of-the-art components and a comprehensive, user-friendly software.

- Bioreactor systems for cell culture and microbial cultivation (15-15,000 l wv) customized
- Lab bioreactor systems
- Media/buffer preparation and storage systems
- Purification systems
- CIP/SIP units
- High Pressure CIP units (90barg)
- Thermal inactivation unit

Our services cover the total life cycle of the system, making Bilfinger Bioreactor a secure investment.

- Project Consulting Pharma Plant
- Engineering Service
- Experimental plants test
- Test running in collaboration with Universities in Europe or Asia
- After Sale Service

In China, we are looking for customers from the biopharma industry, for collaboration partners and for partners for business development and clinical development.

我们设计、制造、组装用于生物技术、制药和精细化工行业的管道、系统和设备。我们公司通过遍布奥地利、德国、瑞士、中国、韩国及东欧的网点，来服务当地的客户。在 50 多年的时间里，我们始终运用自身广博的知识和结构化的方法。如今公司的知名度已远播萨尔茨堡之外。

我们为微生物发酵和细胞培养提供创新的不锈钢生物反应器生产线。这项模块化的设计使用了最先进的组件，并配备了一个全面且用户友好的软件。

- 用于细胞培养和微生物培养（15-15,000 l wv）的定制的生物反应器系统
- 实验室生物反应器系统
- 介质/缓冲液的配制和存储系统
- 净化系统
- 在线清洗和在线灭菌
- 高压在线清洗（90巴）
- 热失活组件

我们的服务涵盖了系统的整个生命周期，因此Bilfinger的生物反应器是一项安全的投资。

- 为制药工厂提供项目咨询
- 工程服务
- 试验工厂的测试
- 与欧洲或亚洲的大学合作进行运行测试
- 售后服务

我们正在中国寻找来自生物医药行业的客户、潜在的合作项目以及可以共同发展业务、进行临床开发的合作伙伴。

HOOKIPA BIOTECH AG

Hookipa Biotech AG
Mariahilfer Straße 123/3. Stock
1060 Vienna, Austria
E: office@hookipabiotech.com
W: www.hookipabiotech.com

Business Scope:
Hookipa Biotech is a start-up company founded in Vienna, Austria, in summer 2011. The company´s mission is to develop innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave™ technology.

The Vaxwave™ technology presents a novel vaccine platform based on replication-defective viral vectors. The platform has become recognized as one of the most promising new strategies for next generation vaccines due to its unique strength for stimulating both potent B cell and T cell immune responses. Vaxwave™ has been validated in various disease models and has the potential of opening the field to a wide range of applications including persistent viral infections and cancer.

In October 2011, Hookipa has raised € 7 million from internationally renowned venture capital investors, namely Sofinnova Partners and Forbion Capital Partners. The company currently focuses on the development of its lead vaccine candidate HB101 and plans to further industrialize the Vaxwave™ technology and build a robust pre-clinical product pipeline.

业务领域：
Hookipa 生物技术股份公司是 2011 年夏天创办于奥地利维也纳的朝气蓬勃的企业。基于 Vaxwave™ 专利技术，公司致力于预防性与治疗性疫苗的研发。

我公司的 Vaxwave™ 专利技术，开创了一个基于复制缺陷病毒载体的新型疫苗平台。由于能同时有效刺激 B 和 T 潜能细胞的免疫反应，这一平台代表了新一代疫苗产品的方向。Vaxwave™ 专利技术已经在不同的疾病模型中得到了验证，并具备了被应用于包括持续性病毒感染和癌症在内的更多疾病类型的潜能。

2011 年 10 月，Hookipa 公司吸引了国际知名风投（即：Sofinnova Partners 和 Forbion Capital Partners 公司）的 700 万欧元注资。公司目前正致力于其主打疫苗“HB101”的研发，并计划推进 Vaxwave™ 专利技术的产业化，形成健全的临床前产品开发平台。